Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 20/20 | 0.53 |
| ▸ | CA1 | P00915 | 20/20 | 0.53 |
| ▸ | CA2 | P00918 | 20/20 | 0.53 |
| ▸ | CA4 | P22748 | 20/20 | 0.53 |
| ▸ | CA7 | P43166 | 20/20 | 0.53 |
| ▸ | CA9 | Q16790 | 20/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15129505 | 0.94 | KMT2A (0.51) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2145523 | 0.92 | HRH3 (0.48) | CA12CA1CA2CA4CA7 | |
| SCHEMBL997974 | 0.85 | TRPV1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL15206576 | 0.85 | TRPV1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL15205294 | 0.85 | TRPV1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4780968 | 0.85 | CA12 (0.49) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5216841 | 0.82 | DPP4 (0.52) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4212961 | 0.82 | DPP4 (0.52) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5575433 | 0.82 | TRPV1 (0.66) | CA12CA1CA2CA4CA7 | |
| SCHEMBL529863 | 0.82 | MAP4K4 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | CA12 2577/4885CA1 1360/4885CA2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.